id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-0475-0006,FDA,FDA-2013-E-0475,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2015-12-28T05:00:00Z,2015,12,2015-12-28T05:00:00Z,,2015-12-29T01:58:32Z,,0,0,0900006481dd6019
FDA-2013-E-0475-0005,FDA,FDA-2013-E-0475,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ELVITEGRAVIR",Notice,Determinations,2015-04-13T04:00:00Z,2015,4,2015-04-13T04:00:00Z,2015-10-14T03:59:59Z,2015-04-13T13:49:37Z,2015-08362,0,0,0900006481aa1d2c